FDA approves Cytyc's ThinPrep Pap test:
This article was originally published in Clinica
The US FDA has approved Cytyc's PMA supplement application for permission to include data describing the detection of high-grade squamous intraepithelial lesions (HSIL) with the firm's ThinPrep Pap cervical cancer test. The data, from a multi-site clinical outcomes trial will now be included in the Cytyc's package insert that accompanies the ThinPrep system, says the Boxborough, Massachusetts firm. The American College of Obstetricians and Gynecologists recommends that women with a cytology specimen suggesting the presence of HSIL should undergo colposcopic examination and directed biopsy, the company adds.
You may also be interested in...
With many non-CE marked products being allowed onto various EU member state markets, who is going to monitor compliance? TÜV-SÜD’s Bassil Akra calls for cooperation to avoid unsafe products being used on patients.
Indian drug makers appear confident of meeting both domestic and global requirements for hydroxychloroquine sulphate after India relaxed export curbs on the product, subject to strict monitoring, against the backdrop of requests from global heads of government for supplies of the potential treatment for COVID-19.
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.